Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

This study has been completed.
Information provided by:
Callisto Pharmaceuticals Identifier:
First received: June 28, 2004
Last updated: December 20, 2007
Last verified: December 2007

This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.

Condition Intervention Phase
Multiple Myeloma
Drug: Atiprimod
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Callisto Pharmaceuticals:

Primary Outcome Measures:
  • The primary objective of this study is to identify the maximum tolerated dose [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The secondary objective of this study is to measure the pharmacokinetics of [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Enrollment: 30
Study Start Date: May 2004
Study Completion Date: November 2007
Intervention Details:
    Drug: Atiprimod
    Oral, once a day, 14 days on 14 days off
Detailed Description:

This is a multi-center, open-label, dose escalation study intended to identify the MTD of atiprimod alone and the MTD of atiprimod when given in combination with ursodiol. The atiprimod dose will be escalated in sequential cohorts. Ten dose levels of atiprimod are planned for the atiprimod alone dose escalation: 30, 60, 90, 120, 180, 240, 300, 360, 420, and 480 mg/day to be given orally. Six dose levels of atiprimod are planned for the atiprimod in combination with ursodiol dose escalation: 180, 240, 300, 360, 420, and 480 mg/day to be given orally. The dose of ursodiol will remain constant for all cohorts (300 mg ursodiol orally three times a day everyday). Up to 105 patients will participate depending on the level at which toxicity is observed. Patients will be assigned to dose level in the order of study entry.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • documented history of multiple myeloma,
  • failed at least two prior regimens for multiple myeloma,
  • 18 years of age or older,
  • ECOG(Zubrod)PS of 0 to 2,
  • screening evaluation for determining eligibility prior to enrollment,
  • signed informed consent form,

Exclusion Criteria:

  • concomitant therapy medications including corticosteroids or other chemotherapy that is or may be active against myeloma ,
  • renal insufficiency (serum creatinine levels of > 2mg/dL),
  • mucosal bleeding,
  • any condition which in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study.
  • clinically relevant active infection or co-morbid medical conditions.
  • prior malignancy(within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient is has been disease-free for at least 3 years.
  • patients with non-secretory myeloma.
  • as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00086216

United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Callisto Pharmaceuticals
Study Director: Gary Jacob, PhD Callisto Pharmaceuticals
  More Information

No publications provided

Responsible Party: Gary Jacob, Callisto Pharmaceuticals Identifier: NCT00086216     History of Changes
Obsolete Identifiers: NCT00301977, NCT00491972
Other Study ID Numbers: CP-101, efficacy, pharmacokinetics, research markers
Study First Received: June 28, 2004
Last Updated: December 20, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Callisto Pharmaceuticals:
Multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Vascular Diseases processed this record on November 20, 2014